Immobilized Obinutuzumab derived Anti-CD20 antibody, Human IgG1 at 2 μg/mL (100 μL/well) can bind Recombinant Human CD20-Nanodisc (Full Length) Protein (Cat: 11007-H93H-NB), the EC50 is 1-5 ng/mL. |
Immobilized Rituximab derived Anti-CD20 antibody, Human IgG1 at 2 μg/mL (100 μL/well) can bind Recombinant Human CD20-Nanodisc (Full Length) Protein (Cat: 11007-H93H-NB), the EC50 is 2-8 ng/mL. |
Immobilized Recombinant Human CD20 Protein (Nanodisc, Full-length, Strep & His Tag) (Cat: 11007-H93H-NB) at 5 μg/mL (100 μL/well) can bind Obinutuzumab derived Anti-CD20 antibody, Human IgG1, the EC50 is 4.0-12.0 ng/mL (Routinely tested). |
Loaded Obinutuzumab on proA Biosensor, can bind Recombinant Human CD20 Protein, Nanodisc, Full-length, Strep & His Tag (Cat. No. 11007-H93H-NB) with an affinity constant of 11.000 nM as determined in BLI assay (Sartorius Octet RED384) (Routinely tested). |
Loaded Rituximab on proA Biosensor, can bind Recombinant Human CD20 Protein, Nanodisc, Full-length, Strep & His Tag (Cat. No. 11007-H93H-NB) with an affinity constant of 14.800 nM as determined in BLI assay (Sartorius Octet RED384) (Routinely tested). |
Cancer Drug Targets
Tedder TF, et al. (1988) Isolation and structure of a cDNA encoding the B1 (CD20) cell-surface antigen of human B lymphocytes. Proc Natl Acad Sci. 85(1): 208-12.
Cragg MS, et al. (2005) The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun. 8: 140-74..
Polyak MJ, et al. (2003) A cholesterol-dependent CD20 epitope detected by the FMC7 antibody. Leukemia. 17(7): 1384-9.
400-829-0116